University College London: Groundbreaking Bowel Cancer Trial Follow-up Shows Zero Relapses
April 21, 2026
April 21, 2026
LONDON, England, April 21 -- The University College London posted the following news:
* * *
Groundbreaking bowel cancer trial follow-up shows zero relapses
Patients with a specific bowel cancer who were given short-course immunotherapy before surgery, instead of post-op chemotherapy, remained cancer-free after nearly three years of follow-up, according to new results from the NEOPRISM-CRC trial led by UCL and UCLH.
The latest findings, to be pr . . .
* * *
Groundbreaking bowel cancer trial follow-up shows zero relapses
Patients with a specific bowel cancer who were given short-course immunotherapy before surgery, instead of post-op chemotherapy, remained cancer-free after nearly three years of follow-up, according to new results from the NEOPRISM-CRC trial led by UCL and UCLH.
The latest findings, to be pr . . .